StockSelector.com
  Research, Select, & Monitor Sunday, February 16, 2020 2:49:13 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Dicerna Pharmaceuticals Inc$21.27($.22)(1.02%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Dicerna Pharmaceuticals Inc has an overall rank of 2077 out of 5787 stocks based on 4 positive rankings and 2 negative rankings.

Positive Rankings
Target Prices
The average analysts' target price is $30.00 for Dicerna Pharmaceuticals Inc using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Dicerna Pharmaceuticals Inc is ranked 192.
90 Day Gain
Dicerna Pharmaceuticals Inc rank is 447
Low/Rising MACD
The MACD remains negative, but is rising... suggesting a possible near-term correction. Of companies with a negative, but rising MACD, Dicerna Pharmaceuticals Inc is ranked 835.
10 Day Gain
Dicerna Pharmaceuticals Inc rank is 973
Negative Rankings
High vPut/Call
Dicerna Pharmaceuticals Inc has a high Put/Call ratio of 2.98 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Dicerna Pharmaceuticals Inc is ranked 337.
High Put/Call
Dicerna Pharmaceuticals Inc has a high Put/Call ratio of 1.22 on all open interest of options expiring in the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Dicerna Pharmaceuticals Inc is ranked 609.







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2020 StockSelector.com. All rights reserved.